More recently, improved understanding of the underlying cause of eczema has spurred the development of a new, safe and effective systemic treatment called Dupixent. This is a self administered injection (every 2 weeks) that addresses the itching and inflammation associated with eczema. By targeting a specific part of the immune system, Dupixent avoids the side effects linked to other systemic treatments.  Currently, it is approved for patients 12 years and older, and trials are being conducted down to 6 years of age. In 2017, Dupixent became the first systemic FDA approved therapy for moderate to severe atopic dermatitis. In the “SOLO 1” and “SOLO 2” studies, approximately 37% of patients with moderate to severe atopic dermatitis were clear or almost clear after 16 weeks of therapy. Since its release, Dupixent has shown even better results in clinical practice. The most commonly reported adverse events in the treatment groups were injection site reaction (temporary redness and swelling) and pink eye (conjunctivitis). No patients dropped out of the study because of injection site reactions and one patient discontinued because of conjunctivitis. Note that pinkeye is often easily treatable with topical eyedrops. Patients who start Dupixent should plan on remaining on this medication indefinitely as there is currently no cure for eczema.